Stocks to see: Mylan NV (MYL), Amgen, Inc. (AMGN)



Stock’s Trading Stats:

Mylan NV (NASDAQ:MYL) declined -0.07% yesterday and closed at $44.99. The company’s market capitalization is at $22.08 billion with an average trading volume of 4.65 Million. The total number of Outstanding Shares Held by the company are 490.69 Million.

Recent Press Release:

Mylan N.V. (MYL) on April 19, 2016 declared that it will host a conference call and live webcast, on Tuesday, May 3, 2016, at 10 a.m. EDT, to review the company’s financial results for the first quarter ended March 31, 2016. Mylan will release its financial results on May 3, before the open of the U.S. financial markets.

The dial-in number to access the earnings call is 800.514.4861 or 678.809.2405 for international callers. To access the live webcast, please log on to Mylan’s website,, at least 15 minutes before the event is planned to start to register and download or install any necessary software. A replay of the webcast will be accessible at, for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, counting antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in about 165 countries and territories. Our global R&D and manufacturing platform comprises more than 50 facilities, and we are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our nearly 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at

Amgen, Inc. (NASDAQ:AMGN):

Stock’s Trading Stats:

Amgen, Inc. (NASDAQ:AMGN) closed at $162.85 yesterday by showing a decrease of -0.37%. The total number of outstanding shares held by the company are 752.09 Million with the total market capitalization of $122.34 billion. The number of shares traded on the last trading session are 2.16 Million.

Recent Press Release:

Amgen Inc. (AMGN) on April 25, 2016 declared that it will report its first quarter financial results on Thursday, April 28, 2016, after the close of the U.S. financial markets. The declarement will be followed by a conference call with the investment community at 2:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen’s senior administration team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be accessible to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by administration at certain investor and medical conferences, can be found on Amgen’s website,, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and accessible for replay for at least 90 days after the event.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach starts by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on